Conduction Slowing

Conduction Slowing refers to the reduction in the speed at which electrical impulses propagate through the cardiac conduction system or myocardial tissue. This phenomenon affects the timing and coordination of cardiac muscle activation, potentially altering normal heart rhythm and function. Conduction slowing can occur in any part of the cardiac conduction pathway, including the sinoatrial (SA) node, atrioventricular (AV) node, His-Purkinje system, or ventricular myocardium, and is influenced by various physiological and pathological factors.

Mechanisms Underlying Conduction Slowing

Cellular Electrophysiology

At the cellular level, conduction velocity depends primarily on the rate of depolarization of the cardiac myocytes and their electrical coupling. The upstroke velocity of the action potential, largely mediated by the fast inward sodium current (I_Na), determines how rapidly depolarization spreads from one cell to the next. A reduction in sodium channel availability or function slows the action potential upstroke, thereby slowing conduction.

Intercellular Coupling

Cardiac myocytes are electrically connected by gap junctions composed mainly of connexin proteins (e.g., connexin43). These gap junctions permit the flow of ions and electrical current between adjacent cells. A decrease in gap junction density or conductance increases resistance to current flow, impeding impulse propagation and contributing to conduction slowing.

Tissue Architecture and Cellular Arrangement

Structural changes such as fibrosis, ischemia, or infarction disrupt the normal alignment and connectivity of myocytes. These alterations increase the heterogeneity of conduction pathways, creating areas of slowed conduction or conduction block. Additionally, increased extracellular matrix deposition or cellular hypertrophy can physically separate cells, further impairing conduction.

Physiological and Pathological Factors Contributing to Conduction Slowing

Ischemia and Hypoxia

Reduced oxygen supply affects ion channel function and cellular metabolism, leading to impaired sodium channel activity and gap junction uncoupling. This results in slower impulse propagation through affected myocardial regions.

Electrolyte Disturbances

Abnormalities in extracellular potassium and calcium levels modify resting membrane potential and channel kinetics. Elevated potassium, for example, depolarizes the resting membrane potential, inactivating sodium channels and diminishing conduction velocity.

Pharmacological Agents

Certain antiarrhythmic drugs, especially Class I sodium channel blockers, reduce the availability of sodium channels during depolarization, thereby slowing conduction. Other drugs may influence gap junction conductance or autonomic tone, indirectly affecting conduction speed.

Structural Heart Disease

Fibrosis, scarring, cardiomyopathies, and infiltrative diseases alter the myocardial substrate, creating regions of slowed or blocked conduction. This heterogeneity can predispose to reentrant arrhythmias by facilitating unidirectional block and slow conduction pathways.

Autonomic Nervous System Influence

Increased vagal tone can slow conduction particularly at the AV node by modulating calcium channels and reducing impulse velocity. Sympathetic stimulation generally enhances conduction velocity by increasing calcium current and excitability.

Clinical Implications of Conduction Slowing

Arrhythmogenesis

Slowed conduction is a critical substrate for reentrant arrhythmias, including atrial fibrillation, atrial flutter, ventricular tachycardia, and certain types of heart block. Areas of conduction slowing create zones where impulses may circulate repeatedly, sustaining arrhythmias.

Conduction Blocks

Marked slowing may progress to conduction block, where impulses fail to propagate beyond a certain point. This can manifest as first-, second-, or third-degree atrioventricular block, bundle branch block, or intraventricular conduction delays, each with distinct electrocardiographic features.

Electrocardiographic Manifestations

Conduction slowing is reflected on the ECG by prolonged PR intervals (atrioventricular conduction delay), widened QRS complexes (intraventricular conduction delay), or abnormal QRS morphology (bundle branch blocks). These changes provide diagnostic clues to underlying conduction system disease.

Measurement and Assessment

Electrophysiological Studies

Invasive intracardiac recordings measure conduction times within specific cardiac structures, allowing precise localization of conduction slowing.

Surface Electrocardiography

Analysis of intervals such as PR, QRS duration, and QT interval on the surface ECG provides indirect evidence of conduction velocity alterations.

Imaging and Histopathology

Cardiac imaging techniques such as MRI can identify structural substrates (fibrosis, scarring) associated with conduction slowing. Histopathological examination confirms cellular and intercellular abnormalities affecting conduction.

Therapeutic Considerations

Pharmacologic Management

Drugs that modulate ion channels or improve gap junction coupling may influence conduction velocity. Careful selection is necessary to avoid exacerbating conduction slowing, especially in patients with pre-existing conduction disease.

Device Therapy

Pacemakers and implantable cardioverter-defibrillators (ICDs) can manage symptoms and prevent complications related to conduction slowing and block by providing electrical stimulation or terminating arrhythmias.

Catheter Ablation

Targeting areas of slow conduction responsible for reentrant circuits can restore normal conduction patterns and prevent arrhythmias.

Conduction slowing represents a complex interplay of electrophysiological and structural factors that influence cardiac impulse propagation. Understanding its mechanisms and implications is essential for accurate diagnosis, risk stratification, and tailored therapeutic interventions in cardiac electrophysiology.